Viz.ai, an artificial intelligence (AI) powered healthcare software provider, has raised $50m through Series B funding round to expand its synchronised stroke care.
San Fransisco-based investment firm Greekoaks led the financing round, with participation from Threshold Ventures, CRV and current investors GV and Kleiner Perkins.
In 2018, the company’s product, Viz LVO, a computer-aided triage and notification software, was given a De Novo clearance by the US Food and Drug Administration (FDA).
The firm uses deep learning algorithms to detect suspected large vessel occlusion, especially the disabling type of stroke, in a CT scan.
Following detection, the stroke team specialist is alerted within minutes, allowing synchronised care and timely treatment.
More than 300 hospitals across the US use Viz.ai’s acute ischemic stroke software.
Viz.ai CEO Chris Mansi said: “Viz.ai’s mission is to improve access to lifesaving treatments. In a stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient.
“This round of funding will enable us to expand the benefits of Synchronised Care to more disease states and geographies, democratising the quality of health care globally.”
Neil Shah of Greenoaks said: “We see Viz.ai as the future of how healthcare is delivered. With rising costs and more focus on value-based care, there needs to be an emphasis on delivering the highest quality care in the shortest amount of time while reducing costs.”
The company, based in San Francisco and Tel Aviv, also secured 510(k) clearance from the US FDA for its Viz CTP, a tool for automated cerebral perfusion image analysis.